Want to see IN:COHANCE full AI Analyst Report?
Suven Pharmaceuticals Ltd. (COHANCE) Ratios
Suven Pharmaceuticals Ltd. Ratios
IN:COHANCE's free cash flow for Q1 2027 was $0.00. For the 2027 fiscal year, IN:COHANCE's free cash flow was increased by $0.00 and operating cash flow was $0.00. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.78 | 2.43 | 11.82 | 6.37 | 5.36 |
| Quick Ratio | 1.91 | 1.98 | 9.65 | 4.40 | 4.02 |
| Cash Ratio | 0.09 | 0.23 | 0.44 | 0.41 | 0.21 |
| Solvency Ratio | 0.22 | 0.29 | 1.74 | 1.99 | 1.63 |
| Operating Cash Flow Ratio | 0.55 | 0.79 | 3.35 | 2.84 | 1.57 |
| Short-Term Operating Cash Flow Coverage | 2.46 | 4.01 | 9.29 | 6.98 | 4.92 |
| Net Current Asset Value | $ 1.00B | $ -3.03B | $ 10.60B | $ 7.80B | $ 8.26B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.07 | 0.09 | 0.03 | 0.04 | 0.05 |
| Debt-to-Equity Ratio | 0.10 | 0.16 | 0.03 | 0.04 | 0.06 |
| Debt-to-Capital Ratio | 0.09 | 0.14 | 0.03 | 0.04 | 0.06 |
| Long-Term Debt-to-Capital Ratio | 0.01 | 0.00 | 0.00 | 0.00 | 0.02 |
| Financial Leverage Ratio | 1.46 | 1.79 | 1.10 | 1.13 | 1.20 |
| Debt Service Coverage Ratio | 2.06 | 3.87 | 7.87 | 6.10 | 6.09 |
| Interest Coverage Ratio | 6.44 | 45.80 | 61.84 | 40.50 | 64.24 |
| Debt to Market Cap | 0.02 | 0.00 | 0.00 | 0.01 | 0.01 |
| Interest Debt Per Share | 11.45 | 11.39 | 2.85 | 3.27 | 4.15 |
| Net Debt to EBITDA | 0.79 | 0.48 | 0.04 | 0.01 | 0.08 |
| Profitability Margins | |||||
| Gross Profit Margin | 40.15% | 68.63% | 57.34% | 56.32% | 56.96% |
| EBIT Margin | 10.77% | 27.40% | 39.29% | 42.72% | 49.23% |
| EBITDA Margin | 19.03% | 33.87% | 44.49% | 46.28% | 52.26% |
| Operating Profit Margin | 10.56% | 47.23% | 43.83% | 38.71% | 41.99% |
| Pretax Profit Margin | 9.13% | 28.72% | 38.59% | 41.76% | 51.76% |
| Net Profit Margin | 7.90% | 22.37% | 28.56% | 30.69% | 35.18% |
| Continuous Operations Profit Margin | 6.62% | 22.11% | 28.56% | 30.69% | 32.00% |
| Net Income Per EBT | 86.57% | 77.89% | 74.02% | 73.48% | 67.98% |
| EBT Per EBIT | 86.39% | 60.80% | 88.04% | 107.89% | 123.26% |
| Return on Assets (ROA) | 3.13% | 8.84% | 13.32% | 20.92% | 24.80% |
| Return on Equity (ROE) | 4.58% | 15.79% | 14.64% | 23.70% | 29.72% |
| Return on Capital Employed (ROCE) | 4.71% | 21.21% | 21.46% | 28.71% | 33.45% |
| Return on Invested Capital (ROIC) | 3.32% | 15.72% | 15.57% | 20.36% | 21.82% |
| Return on Tangible Assets | 4.12% | 11.58% | 13.70% | 21.61% | 24.83% |
| Earnings Yield | 1.56% | 0.97% | 1.76% | 3.42% | 2.88% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.29 | 4.20 | 7.87 | 12.08 | 5.42 |
| Payables Turnover | 4.77 | 4.68 | 10.59 | 12.00 | 5.24 |
| Inventory Turnover | 2.41 | 2.26 | 1.94 | 1.87 | 1.96 |
| Fixed Asset Turnover | 1.05 | 0.96 | 1.34 | 1.75 | 2.30 |
| Asset Turnover | 0.40 | 0.40 | 0.47 | 0.68 | 0.70 |
| Working Capital Turnover Ratio | 2.71 | 1.43 | 1.05 | 1.51 | 2.04 |
| Cash Conversion Cycle | 185.50 | 170.71 | 200.08 | 194.83 | 184.04 |
| Days of Sales Outstanding | 110.85 | 86.81 | 46.40 | 30.21 | 67.31 |
| Days of Inventory Outstanding | 151.15 | 161.82 | 188.15 | 195.03 | 186.36 |
| Days of Payables Outstanding | 76.51 | 77.92 | 34.47 | 30.41 | 69.64 |
| Operating Cycle | 262.01 | 248.63 | 234.55 | 225.24 | 253.67 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 9.29 | 11.26 | 14.09 | 17.71 | 12.96 |
| Free Cash Flow Per Share | 3.53 | 5.18 | 12.05 | 6.49 | 10.01 |
| Dividend Paid and CapEx Coverage Ratio | 1.61 | 1.85 | 6.92 | 0.92 | 1.86 |
| Capital Expenditure Coverage Ratio | 1.61 | 1.85 | 6.92 | 1.58 | 4.39 |
| Operating Cash Flow Coverage Ratio | 0.89 | 1.03 | 5.52 | 6.41 | 3.40 |
| Operating Cash Flow to Sales Ratio | 0.16 | 0.24 | 0.34 | 0.34 | 0.26 |
| Free Cash Flow Yield | 1.17% | 0.48% | 1.80% | 1.37% | 1.62% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 64.28 | 102.78 | 56.75 | 29.24 | 34.69 |
| Price-to-Sales (P/S) Ratio | 5.08 | 22.94 | 16.21 | 8.97 | 12.21 |
| Price-to-Book (P/B) Ratio | 2.95 | 16.20 | 8.31 | 6.93 | 10.31 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 85.28 | 207.45 | 55.57 | 72.82 | 61.78 |
| Price-to-Operating Cash Flow Ratio | 32.45 | 95.35 | 47.54 | 26.67 | 47.71 |
| Price-to-Earnings Growth (PEG) Ratio | -1.17 | -8.98 | -2.10 | -3.12 | 1.37 |
| Enterprise Value Multiple | 27.48 | 68.23 | 36.47 | 19.40 | 23.44 |
| Enterprise Value | 118.61B | 276.70B | 170.60B | 120.31B | 157.96B |
| EV to EBITDA | 27.48 | 68.23 | 36.47 | 19.40 | 23.44 |
| EV to Sales | 5.23 | 23.11 | 16.23 | 8.98 | 12.25 |
| EV to Free Cash Flow | 87.80 | 208.91 | 55.62 | 72.85 | 61.99 |
| EV to Operating Cash Flow | 33.41 | 96.02 | 47.59 | 26.68 | 47.87 |
| Tangible Book Value Per Share | 69.36 | 43.84 | 78.15 | 65.72 | 59.90 |
| Shareholders’ Equity Per Share | 102.35 | 66.32 | 80.58 | 68.16 | 59.99 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.27 | 0.23 | 0.26 | 0.27 | 0.32 |
| Revenue Per Share | 59.36 | 46.81 | 41.31 | 52.65 | 50.67 |
| Net Income Per Share | 4.69 | 10.47 | 11.80 | 16.16 | 17.83 |
| Tax Burden | 0.87 | 0.78 | 0.74 | 0.73 | 0.68 |
| Interest Burden | 0.85 | 1.05 | 0.98 | 0.98 | 1.05 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 |
| SG&A to Revenue | 0.30 | 0.21 | 0.13 | 0.01 | 0.01 |
| Stock-Based Compensation to Revenue | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.98 | 0.84 | 1.19 | 0.81 | 0.49 |
Currency in INR